Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

ClinicalTrials.gov ID: NCT00227305

Public ClinicalTrials.gov record NCT00227305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)

Study identification

NCT ID
NCT00227305
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
381 participants

Conditions and interventions

Interventions

  • quetiapine fumarate Drug

Drug

Eligibility (public fields only)

Age range
10 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2004
Primary completion
Nov 30, 2007
Completion
Nov 30, 2007
Last update posted
Jan 7, 2013

2004 – 2007

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Research Site Dothan Alabama
Research Site Scottsdale Arizona
Research Site Cerritos California
Research Site Riverside California
Research Site Sacramento California
Research Site San Diego California
Research Site Denver Colorado
Research Site Altamonte Springs Florida
Research Site Jacksonville Florida
Research Site Miami Florida
Research Site Chicago Illinois
Research Site Oak Brook Illinois
Research Site Newton Kansas
Research Site Overland Park Kansas
Research Site New Orleans Louisiana
Research Site Las Vegas Nevada
Research Site Rochester New York
Research Site Cincinnati Ohio
Research Site Cleveland Ohio
Research Site Lyndhurst Ohio
Research Site Oklahoma City Oklahoma
Research Site Philadelphia Pennsylvania
Research Site Memphis Tennessee
Research Site Austin Texas
Research Site Houston Texas
Research Site San Antonio Texas
Research Site Richmond Virginia
Research Site Virginia Beach Virginia
Research Site Bellevue Washington
Research Site Kirkland Washington
Research Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00227305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 7, 2013 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00227305 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →